Morphine currently represents the best option for the management of severe pain and chronic pain states. Prolonged use of opiates often produces the need for ever- increasing doses to maintain pain relief, also known as analgesic tolerance. The mechanisms associated with analgesic tolerance are thought to due to morphine- induced cellular adaptations that produce a state of heightened pain or hyperalgesia. Recent studies suggest that opiates acting via the mu-opioid receptor can induce expression of chemokines and their receptors. Previous works from our laboratory demonstrate that some of these same chemokines/receptors have been shown to play central roles in chronic pain states. To uncover evidence of possible links between chronic morophine treatment, chemokine signaling and analgesic tolerance, we propose the hypothesis that opiate-induced chemokine signaling is central to analgesic tolerance.
Our specific aims i nclude 1) a characterization of the chronology of cellular/signaling events associated with opiate-induced hyperalgesia 2) explore mechanisms by which morphine induces chemokine/receptor expression in the dorsal root ganglia and 3) examine the cellular/molecular mechanisms by which chronic morphine treatment enhances chemokine signaling. Better understanding of these chemokine/receptor- mediated events may provide the necessary framework for the design of agents that counteract deleterious opiate-induced cellular adaptations and effectively reduce analgesic tolerance.
Morphine is a powerful pain reliever for cancer and non-cancer pain, but also a potent inducer of tolerance. Opiate tolerance refers to a phenomenon in which exposure to a opiate results in the diminution of an analgesic effect (pain relief). Tolerance to the analgesic effect of morphine is a poorly understood phenomenon and can clearly present major management difficulties in some patients. Better understanding of the events associated with the development of tolerance may provide the necessary framework for the design of agents effectively reduce analgesic tolerance.
|Wilson, Natalie M; Ripsch, Matthew S; White, Fletcher A (2016) Impact of Opioid and Nonopioid Drugs on Postsurgical Pain Management in the Rat. Pain Res Treat 2016:8364762|
|Park, Ki Duk; Yang, Xiao-Fang; Dustrude, Erik T et al. (2015) Chimeric agents derived from the functionalized amino acid, lacosamide, and the Î±-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosami ACS Chem Neurosci 6:316-30|
|Due, Michael R; Yang, Xiao-Fang; Allette, Yohance M et al. (2014) Carbamazepine potentiates the effectiveness of morphine in a rodent model of neuropathic pain. PLoS One 9:e107399|
|Due, Michael R; Park, Jonghyuck; Zheng, Lingxing et al. (2014) Acrolein involvement in sensory and behavioral hypersensitivity following spinal cord injury in the rat. J Neurochem 128:776-86|
|Allette, Yohance M; Due, Michael R; Wilson, Sarah M et al. (2014) Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain. Brain Behav Immun 42:169-77|
|Ju, Weina; Li, Qi; Allette, Yohance M et al. (2013) Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. J Neurochem 124:869-79|
|Ripsch, Matthew S; Ballard, Carrie J; Khanna, May et al. (2012) A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY. Transl Neurosci 3:1-8|
|Wilson, Sarah M; Schmutzler, Brian S; Brittain, Joel M et al. (2012) Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides. J Biol Chem 287:35065-77|
|Deng, Liting; Guindon, Josee; Vemuri, V Kiran et al. (2012) The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CBÃ½Ã½Ã½ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 8:71|
|King, Amber M; Yang, Xiao-Fang; Wang, Yuying et al. (2012) Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation. ACS Chem Neurosci 3:1037-49|
Showing the most recent 10 out of 35 publications